



Presage Biosciences Named a “Fierce 15” Biotech Company of 2013 by FierceBiotech

SEATTLE, Wash. – September 24, 2013 – Presage Biosciences, a leader in precision oncology, has been named by FierceBiotech as one of 2013’s Fierce 15 biotechs, designating it as one of the most promising private biotechnology companies in the industry. This is FierceBiotech's eleventh annual Fierce 15 selection.

“Dr. James Olson has embarked on a quest to take the guesswork out of cancer treatment for the benefit of patients like his own, and Presage Biosciences shows how team science can help make big ideas in biomedicine into reality,” says Ryan McBride, the executive editor at FierceBiotech. “This biotech has helped secure Olson’s reputation as one of Seattle’s most innovative entrepreneurs in the field.”

“We are honored to be recognized as one of the “Fierce 15” by FierceBiotech,” said Jim Olson, M.D., Founder and Chairman of the Board of Directors of Presage. “At Presage, we are dedicated to improving cancer drug development so that patients can receive the most effective treatment possible.”

Presage Biosciences’ patented CIVO™ precision oncology platform offers an entirely novel method for simultaneously analyzing multiple cancer drug candidates and drug combinations within a single tumor while that tumor is still in a patient. CIVO is currently being evaluated in a Phase 1 clinical trial designed to evaluate the feasibility of assessing lymphoma response to multiple microinjected candidate chemotherapy agents.

The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position. A complete list of "Fierce 15"

companies – the online newsletter's tenth annual selection – is available online at www.FierceBiotech.com.

About FierceBiotech

FierceBiotech is the biotech industry's daily monitor - a free email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval and regulation, biotech company deals and more. More than 90,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Signing up is free.

About Presage Biosciences

Presage Biosciences is a leader in precision oncology. In addition to developing the CIVO™ precision oncology platform, the company is driving discovery of effective drug combinations. Presage partners with oncology-focused pharmaceutical companies through strategic alliances to provide previously inaccessible *in vivo* data to validate novel targets, promote drug candidates to the right indications, and discover effective drug combinations. Presage's CIVO is the world's only known technology to perform simultaneous comparisons of multiple drugs within a living tumor. Presage is privately held and based in Seattle. For more information, visit www.presagebio.com.

#

Presage Contact:

Julie Rathbun
Rathbun Communications
julie@rathbuncomm.com
(206) 769-9219